Sangamo Therapeutics

News

Sangamo cues up Fabry gene therapy filing on STAAR data

Sangamo plans to file for approval of its gene therapy for Fabry disease next year, but a launch could depend on finding a commercial partner.

News

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.

News

Pfizer ducks out of Sangamo haemophilia A alliance

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

News

Can Pfizer, Sangamo energise haemophilia A gene therapy?

There has been a gene therapy on the market for people with the bleeding disorder haemophilia A since 2022, but take-up has been very slow.

News

Sangamo sheds staff once again in another retreat

Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused

News

Double blow for Sangamo as Novartis, Biogen exit deals

The two deals for gene-modifying candidates were worth up to $3.1 billion including milestones.

Sangamo cues up Fabry gene therapy filing on STAAR data

Lilly throws lifeline to Sangamo with $1.4bn licensing deal

Pfizer ducks out of Sangamo haemophilia A alliance

Can Pfizer, Sangamo energise haemophilia A gene therapy?

Sangamo sheds staff once again in another retreat

Double blow for Sangamo as Novartis, Biogen exit deals

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Sangamo Therapeutics

Editor's Picks